|
Delayed
Nasdaq
12:48:22 30/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 10.28 USD | -3.20% |
|
-1.53% | +67.15% |
| 13/10 | ImmuCell Q3 Preliminary Sales Rise | MT |
| 13/10 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Company Valuation: ImmuCell Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 42.92 | 61.94 | 47.26 | 39.45 | 45.89 | 55.63 |
| Change | - | 44.32% | -23.7% | -16.51% | 16.33% | 21.22% |
| Enterprise Value (EV) 1 | 45.7 | 62.02 | 53.94 | 55.16 | 57.24 | 65.02 |
| Change | - | 35.71% | -13.03% | 2.26% | 3.76% | 13.6% |
| P/E | -42x | -776x | -18.9x | -6.79x | -19.5x | -51.3x |
| PBR | 1.52x | 1.9x | 1.56x | 1.58x | 1.68x | 2.06x |
| PEG | - | 8.4x | -0x | -0x | 0.3x | 0.9x |
| Capitalization / Revenue | 2.8x | 3.22x | 2.55x | 2.26x | 1.73x | 2.01x |
| EV / Revenue | 2.98x | 3.22x | 2.91x | 3.16x | 2.16x | 2.35x |
| EV / EBITDA | 47.3x | 22.8x | 286x | -22x | 39.4x | 12.6x |
| EV / EBIT | -33.1x | 241x | -23.5x | -10.6x | -46.4x | 26.5x |
| EV / FCF | -21.2x | -37.9x | -11.7x | -12.2x | 55.7x | 65.1x |
| FCF Yield | -4.72% | -2.64% | -8.54% | -8.17% | 1.8% | 1.54% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.1417 | -0.0103 | -0.322 | -0.75 | -0.2641 | -0.12 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 15.34 | 19.24 | 18.57 | 17.47 | 26.49 | 27.64 |
| EBITDA 1 | 0.9669 | 2.719 | 0.1886 | -2.504 | 1.454 | 5.179 |
| EBIT 1 | -1.38 | 0.2574 | -2.299 | -5.221 | -1.233 | 2.449 |
| Net income 1 | -1.022 | -0.0783 | -2.494 | -5.775 | -2.157 | -1.04 |
| Net Debt 1 | 2.787 | 0.089 | 6.688 | 15.71 | 11.34 | 9.388 |
| Reference price 2 | 5.95 | 8.00 | 6.10 | 5.09 | 5.15 | 6.15 |
| Nbr of stocks (in thousands) | 7,213 | 7,742 | 7,747 | 7,751 | 8,912 | 9,046 |
| Announcement Date | 30/3/21 | 30/3/22 | 29/3/23 | 1/4/24 | 28/3/25 | 30/3/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 96.45M | |
| 37.84x | 13.27x | 28.43x | 0.53% | 1,148B | |
| 39.67x | 6.67x | 18.75x | 1.97% | 652B | |
| 37.4x | 8.39x | 17.35x | 2.4% | 505B | |
| 21.45x | 5.21x | 12.93x | 2.51% | 384B | |
| 102.73x | 5.76x | 24.72x | 2.42% | 348B | |
| 21.89x | 5.76x | 13.88x | 2.85% | 294B | |
| 22.21x | 4.49x | 12.82x | 1.97% | 264B | |
| 28.66x | 7.33x | 13.12x | 2.23% | 244B | |
| -45.79x | 7.11x | 27.55x | 2.07% | 197B | |
| Average | 29.56x | 7.11x | 18.84x | 2.11% | 403.73B | |
| Weighted average by Cap. | 35.29x | 8.40x | 20.64x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ICCC Stock
- Valuation ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions
